News & Trends - Biotechnology

Sanofi’s vaccine for first national influenza program to target children

Health Industry Hub | April 27, 2020 |
[Total: 1    Average: 4/5]

More than a million Australian children aged between 6 months and under 5 years can now receive a FREE influenza vaccine as part of the first National Immunisation Program to include all children in this age group.

The Sanofi Pasteur influenza vaccine VAXIGRIP TETRA will be used to vaccinate these children under the 2020 National Immunisation Program (NIP), which aims to improve national immunisation coverage by providing free vaccines to eligible people.

This coincides with World Immunisation Week – celebrated 24 to 30 April – and aims to promote the use of vaccines to protect people of all ages against disease. #VaccinesWork for All

Dr Sarah Chu, General Practitioner at the Turbot Street Medical Centre, Brisbane, said “Last year, in children under 5 years of age there were 36,569 reported cases of laboratory confirmed influenza and an estimated 5,000 related hospitalisations.”

Dr Chu said “There has been a lot of focus on influenza in older Australians, but hospitalisation rates in children are too high for a virus that is preventable. Vaccination remains the most effective way to protect children against influenza.”

Register FREE and join 22,000+ industry professionals receiving the latest industry news and engaging content from Health Industry Hub, the ONLY one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals.

As Australia works to contain and cope with the COVID-19 pandemic, Dr Chu said the community needs to do all it can to minimise avoidable hospitalisations, reduce transmission of influenza, and the “double-whammy of infection with influenza and the coronavirus.”

Dr Chu said that many GPs had introduced protective measures for patients visiting their clinics and that the “stay at home message does not mean foregoing vaccination ahead of the flu season. An annual influenza vaccination is recommended for all Australians from 6 months and over.”

Sanofi Pasteur Australia and New Zealand Medical Director, Dr Christian Felter welcomed the extension of the NIP age range and the start of this year’s world-leading vaccination program. “A national approach to vaccinating children against influenza is a positive step – for families, the community and our health system,” he said.

You may also like PRIME Awards 2020 call for entries – the only awards program dedicated to recognising excellence within Australian healthcare communications, is now open for entries.

“Vaccinating children against influenza not only protects them but helps to reduce influenza transmission to other vulnerable groups in the community, including those with existing health conditions such as cardiovascular disease and people aged 65 and above.”  

In previous years, free influenza vaccination under the NIP was only available to children at high risk of complications, including those with underlying health conditions and children from Aboriginal and Torres Strait Islander communities.

“This is not the year to be complacent about the influenza vaccine. It can protect you, safeguard people around you and hopefully ease the pressure on our overburdened medical system,” Dr Felter said.

This year, the four strains contained in all influenza vaccines are A/Brisbane/02/2018 (H1N1), A/South Australia/34/2019 (H3N2), B/Washington/02/2019, and B/Phuket/3073/2013. 

HCP engagement during COVID-19. Fill the gap of reduced field force activities. Health Industry Hub combines expertise in delivering digital health content with high engagement and 20+ years industry experience. Created by industry for industry. Contact us.

About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

News & Trends - Medical Technology

MedTech News - Private health insurer looking to invest in Australian private hospitals

Private health insurer looking to invest in Australian private hospitals

Health Industry Hub | July 15, 2020 |

MedTech News: In a recent opinion piece Dr Bill Coote, former AMA Secretary General and former Director of the Medicare […]


News & Trends - Pharmaceuticals

Pharma News - Merck Australia supports the first Australian-developed COVID-19 vaccine - Sypharma and Vaxine

Merck Australia supports the first Australian-developed COVID-19 vaccine

Health Industry Hub | July 15, 2020 |

Pharma News: Sypharma, an Australian biopharmaceutical formulation company, announced manufacturing of COVAX-19 and Advax adjuvant for Covid-19 in partnership with […]


News & Trends - Pharmaceuticals

Pharma News - Precision prescribing to combat Australia’s expected surge in mental illness

Precision prescribing to combat Australia’s expected surge in mental illness

Health Industry Hub | July 15, 2020 |

Pharma News: COVID-19 social isolation, familial and community disconnection, shock, job loss and health fears create the perfect storm for […]



Medical Pharma Biotech MedTech - $47M accelerator program for MedTech, Biotech and Pharma sectors in diabetes and cardiovascular disease

$47M accelerator program for MedTech, Biotech and Pharma sectors in diabetes and cardiovascular disease

Health Industry Hub | July 15, 2020 |

Medical News: The operation of the Australian Government’s $47 million Targeted Translation Research Accelerator (TTRA) initiative for diabetes and cardiovascular […]